Doxa AB (publ) (DOXA.ST)
SEK 0.35
(-1.82%)
SEK 0.35
(-1.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -102.2 Million SEK | -85.48% |
| 2022 | -55.1 Million SEK | -264.9% |
| 2021 | -15.1 Million SEK | -229.48% |
| 2020 | -4.58 Million SEK | 3.37% |
| 2019 | -4.74 Million SEK | 67.72% |
| 2018 | -14.69 Million SEK | -57.21% |
| 2017 | -9.34 Million SEK | -858.69% |
| 2016 | 1.23 Million SEK | 131.78% |
| 2015 | -3.87 Million SEK | 75.49% |
| 2014 | -15.82 Million SEK | -1802.91% |
| 2013 | 929 Thousand SEK | 111.14% |
| 2012 | -8.33 Million SEK | 3.54% |
| 2011 | -8.64 Million SEK | -334.06% |
| 2010 | 3.69 Million SEK | 178.69% |
| 2009 | -4.69 Million SEK | -180.18% |
| 2008 | -1.67 Million SEK | -108.79% |
| 2007 | 19.06 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -11.8 Million SEK | 52.03% |
| 2024 Q1 | -24.6 Million SEK | 75.93% |
| 2023 Q4 | -102.2 Million SEK | -127.11% |
| 2023 Q3 | -45 Million SEK | 69.18% |
| 2023 Q2 | -146 Million SEK | -93.63% |
| 2023 Q1 | -75.4 Million SEK | -36.84% |
| 2023 FY | -102.2 Million SEK | -85.48% |
| 2022 Q1 | -275 Million SEK | -1721.19% |
| 2022 FY | -55.1 Million SEK | -264.9% |
| 2022 Q3 | -139 Million SEK | 12.25% |
| 2022 Q4 | -55.1 Million SEK | 60.36% |
| 2022 Q2 | -158.4 Million SEK | 42.4% |
| 2021 Q2 | 400 Thousand SEK | 113.79% |
| 2021 FY | -15.1 Million SEK | -229.48% |
| 2021 Q3 | -194.6 Million SEK | -48750.0% |
| 2021 Q4 | -15.1 Million SEK | 92.24% |
| 2021 Q1 | -2.9 Million SEK | 36.72% |
| 2020 Q4 | -4.58 Million SEK | -179.02% |
| 2020 Q3 | 5.8 Million SEK | 152.17% |
| 2020 Q2 | 2.3 Million SEK | 243.75% |
| 2020 Q1 | -1.6 Million SEK | 66.27% |
| 2020 FY | -4.58 Million SEK | 3.37% |
| 2019 Q3 | -7.9 Million SEK | 21.78% |
| 2019 Q4 | -4.74 Million SEK | 39.96% |
| 2019 FY | -4.74 Million SEK | 67.72% |
| 2019 Q1 | -14.4 Million SEK | 2.0% |
| 2019 Q2 | -10.1 Million SEK | 29.86% |
| 2018 Q3 | -17.6 Million SEK | 17.37% |
| 2018 Q4 | -14.69 Million SEK | 16.51% |
| 2018 Q2 | -21.3 Million SEK | -261.02% |
| 2018 FY | -14.69 Million SEK | -57.21% |
| 2018 Q1 | -5.9 Million SEK | 36.88% |
| 2017 Q2 | 7.4 Million SEK | 117.65% |
| 2017 Q1 | 3.4 Million SEK | 175.97% |
| 2017 FY | -9.34 Million SEK | -858.69% |
| 2017 Q3 | 9.9 Million SEK | 33.78% |
| 2017 Q4 | -9.34 Million SEK | -194.41% |
| 2016 Q3 | -3.2 Million SEK | -10.34% |
| 2016 FY | 1.23 Million SEK | 131.78% |
| 2016 Q4 | 1.23 Million SEK | 138.5% |
| 2016 Q2 | -2.9 Million SEK | 53.23% |
| 2016 Q1 | -6.2 Million SEK | -59.92% |
| 2015 FY | -3.87 Million SEK | 75.49% |
| 2015 Q3 | -1.6 Million SEK | 74.6% |
| 2015 Q2 | -6.3 Million SEK | 42.73% |
| 2015 Q1 | -11 Million SEK | 30.47% |
| 2015 Q4 | -3.87 Million SEK | -142.31% |
| 2014 FY | -15.82 Million SEK | -1802.91% |
| 2014 Q4 | -15.82 Million SEK | -1030.0% |
| 2014 Q3 | -1.4 Million SEK | 70.21% |
| 2014 Q2 | -4.7 Million SEK | 53.92% |
| 2014 Q1 | -10.2 Million SEK | -1197.95% |
| 2013 Q4 | 929 Thousand SEK | 132.23% |
| 2013 Q3 | -2.88 Million SEK | 58.86% |
| 2013 FY | 929 Thousand SEK | 111.14% |
| 2013 Q2 | -7 Million SEK | 0.0% |
| 2012 Q4 | -8.33 Million SEK | 0.0% |
| 2012 FY | -8.33 Million SEK | 3.54% |
| 2011 FY | -8.64 Million SEK | -334.06% |
| 2010 FY | 3.69 Million SEK | 178.69% |
| 2009 FY | -4.69 Million SEK | -180.18% |
| 2008 FY | -1.67 Million SEK | -108.79% |
| 2007 FY | 19.06 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AddLife AB (publ) | 5.01 Billion SEK | 102.037% |
| Biotage AB (publ) | -444 Million SEK | 76.982% |
| Bonesupport Holding AB (publ) | -149.86 Million SEK | 31.806% |
| Elekta AB (publ) | 4.46 Billion SEK | 102.287% |
| iZafe Group AB (publ) | -2.65 Million SEK | -3743.55% |
| Ortivus AB (publ) | 4.19 Million SEK | 2537.977% |
| Ortivus AB (publ) | 4.19 Million SEK | 2537.977% |
| Q-linea AB (publ) | -61.33 Million SEK | -66.639% |
| S2Medical AB (publ) | -1.51 Million SEK | -6636.857% |
| Synsam AB (publ) | 2.67 Billion SEK | 103.823% |